Appointment of Ann Berman to Board of Directors
Renalytix Appoints Ann Berman to its Board of Directors
Berman serves on the board of
"We are delighted to have a professional of Ann's capabilities on board as Renalytix enters into a substantial growth phase," said
Preceding her retirement in 2009,
For further information, please contact:
Renalytix plc |
|||
|
Via Walbrook PR |
||
|
|
||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
||
|
|
||
|
|
||
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
||
|
|
||
|
|
||
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
||
|
Mob: 07980 541 893 / 07584 391 303 |
||
About Renalytix
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully distributed and marketed, our expectations regarding reimbursement decisions, our plans for expansion of our business and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
AIM Rule regulatory disclosures
In accordance with Schedule 2(g) of the AIM Rules,
Current |
Past 5 years |
Loews Corporation |
|
|
Eaton Vance Corporation |
Save for the disclosures above, there are no further disclosures to be made in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the